{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:13Z","timestamp":1793068453371,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012173","name":"China-Japan Friendship Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>An 8-year-old female child presented with patchy hair loss for 1 year, accompanied by eyebrow loss for 6 months. Microscopic examination of the hair confirmed the features of active stage alopecia areata, with a Severity of Alopecia Tool (SALT) score of 70%. The diagnosis was severe alopecia areata. The patient had a history of atopic dermatitis since infancy, with recurrent episodes of scattered papules and pruritus for 8 years. Initial treatment involved subcutaneous injections of dupilumab 300mg every 2 weeks for 6 months, resulting in a reduction of SALT score to 20% and improvement of atopic dermatitis symptoms. Discontinuation of Dupilumab and initiation of daily oral Baricitinib at a dose of 2mg for a duration of 5 months. According to the SALT score evaluation, the severity of hair loss was less than 10% and there was significant regrowth of hair. No significant adverse reactions were observed during the treatment period.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1395288","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:28:21Z","timestamp":1718134101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children"],"prefix":"10.3389","volume":"15","author":[{"given":"Huijuan","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingquan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17187","article-title":"Therapeutic management in paediatric alopecia areata: a systematic review","volume":"35","author":"Waskiel-Burnat","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00329-y","article-title":"Scoping review on the use of drugs targeting jak\/stat pathway in atopic dermatitis, vitiligo, and alopecia areata","volume":"9","author":"Montilla","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.0002","article-title":"Trends in prevalence and incidence of alopecia areata, alopecia totalis, and alopecia universalis among adults and children in a us employer-sponsored insured population","volume":"159","author":"Mostaghimi","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","article-title":"Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis","volume":"78","author":"Strazzulla","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.04.077","article-title":"Treatment of pediatric alopecia areata: a systematic review","volume":"86","author":"Barton","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llac104","article-title":"Alopecia areata and risk of atopic and autoimmune conditions: population-based cohort study","volume":"48","author":"Holmes","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14129","article-title":"Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata","volume":"29","author":"Ito","year":"2020","journal-title":"Exp Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.047","article-title":"Autoimmune diseases in adults with atopic dermatitis","volume":"76","author":"Andersen","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.955035","article-title":"An overview of jak\/stat pathways and jak inhibition in alopecia areata","volume":"13","author":"Lensing","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"Jak-stat signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01873-w","article-title":"Baricitinib for the treatment of alopecia areata","volume":"83","author":"Freitas","year":"2023","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-00889-0","article-title":"Alopecia universalis in an adolescent successfully treated with upadacitinib-a case report and review of the literature on the use of jak inhibitors in pediatric alopecia areata","volume":"13","author":"Kolcz","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.3324","article-title":"Association of vitiligo and alopecia areata with atopic dermatitis: a systematic review and meta-analysis","volume":"151","author":"Mohan","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12396","article-title":"T-helper and regulatory t-cell cytokines in the peripheral blood of patients with active alopecia areata","volume":"169","author":"Tembhre","year":"2013","journal-title":"Br J Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/all.13346","article-title":"Alopecia areata is characterized by expansion of circulating th2\/tc2\/th22, within the skin-homing and systemic t-cell populations","volume":"73","author":"Czarnowicki","year":"2018","journal-title":"Allergy"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/biom13040634","article-title":"Dupilumab in inflammatory skin diseases: a systematic review","volume":"13","author":"Olbrich","year":"2023","journal-title":"Biomolecules"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2017.11.020","article-title":"Alopecia areata after dupilumab for atopic dermatitis","volume":"4","author":"Mitchell","year":"2018","journal-title":"Jaad Case Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0301","article-title":"Alopecia areata in severe atopic dermatitis treated with dupilumab","volume":"28","author":"Barroso-Garcia","year":"2018","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1111\/all.15071","article-title":"Phase 2a randomized clinical trial of dupilumab (anti-il-4ralpha) for alopecia areata patients","volume":"77","author":"Guttman-Yassky","year":"2022","journal-title":"Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1395288\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T19:28:23Z","timestamp":1718134103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1395288\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2024.1395288"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1395288","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,6]]},"article-number":"1395288"}}